Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials

Table 5

Multivariate proportional hazards regression model for overall survival.

Variable	HR	95% CI	P value
Age: <65 versus ≥65 years	0.782	0.343–1.784	0.5591
ECOG PS: 0 versus ≥1	0.335	0.160–0.703	0.0038
Visceral metastases: no versus yes	0.599	0.284–1.263	0.1782
Vaccination: yes versus no	0.308	0.127–0.743	0.0088

ECOG PS: Eastern Cooperative Oncology Group performance status; HR: hazard ratio; CI: confidence interval.